Pfizer

Pfizer Inc (PFE) June 2027 Options Trading Begins

Pfizer's mRNA Influenza Vaccine Fails in Clinical Trial Among Seniors, FDA Commissioner Says

Pfizer Valuation After Recent Share Price Rebound: Undervalued or Mispriced?

辉瑞

Pfizer's 15-Minute Chart Triggers MACD & KDJ Death Crosses

Catalyst<ul> <li>Most analysts rate PFE Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Recent Bullish Engulfing and WR Oversold signals in late November and early December point to rebound momentum for PFE.</li> <li>Net outflows across all fund size buckets indicate investor caution or pessimism towards PFE.</li></ul>

Key Factors

Pfizer Inc. (PFE) announced a partnership with 3SBio to advance cancer R&D efforts. Pfizer’s (PFE) experimental mRNA influenza vaccine failed to provide protection for seniors, according to FDA Commissioner Dr. Marty Makary. Pfizer raised its full-year 2025 adjusted EPS guidance to $3–$3.15 following a Q3 beat and increased sales from its antibody-drug conjugate portfolio. Citigroup reinstated a Neutral rating on Pfizer (PFE) and set a price target of $26.

PFE News